BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 16377411)

  • 21. Angiogenesis and gliomas: current issues and development of surrogate markers.
    Jouanneau E
    Neurosurgery; 2008 Jan; 62(1):31-50; discussion 50-2. PubMed ID: 18300890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy.
    Mazeron R; Anderson B; Supiot S; Paris F; Deutsch E
    Cancer Treat Rev; 2011 Oct; 37(6):476-86. PubMed ID: 21546163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting angiogenesis with integrative cancer therapies.
    Yance DR; Sagar SM
    Integr Cancer Ther; 2006 Mar; 5(1):9-29. PubMed ID: 16484711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Process in the mechanisms of endostatin combined with radiotherapy.
    Zhuang HQ; Yuan ZY
    Cancer Lett; 2009 Sep; 282(1):9-13. PubMed ID: 19136200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The interaction of radiation therapy and antiangiogenic therapy.
    O'Reilly MS
    Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiogenesis research: guidelines for translation to clinical application.
    Folkman J; Browder T; Palmblad J
    Thromb Haemost; 2001 Jul; 86(1):23-33. PubMed ID: 11487011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
    van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
    Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.
    Roy V; Perez EA
    Breast Cancer Res Treat; 2009 Jul; 116(1):31-8. PubMed ID: 19101790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Angiogenesis: all a radiation oncologist should know].
    Mazeron R; Bourhis J; Deutsch E
    Cancer Radiother; 2008 Jan; 12(1):50-60. PubMed ID: 18243753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The clinical perspective of angiogenesis inhibitors].
    Radema SA; Witteveen PO; Gebbink MB; Voest EE
    Ned Tijdschr Geneeskd; 2003 Aug; 147(35):1675-80. PubMed ID: 14513538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiangiogenesis: the fifth cancer treatment modality?
    Camp-Sorrell D
    Oncol Nurs Forum; 2003; 30(6):934-44. PubMed ID: 14603351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Angiogenesis and radiotherapy (vessels, anaemia, oxygen and radiosensitivity)].
    Lartigau E
    Bull Cancer; 2007 Jul; 94 Spec No():S197-202. PubMed ID: 17846005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiangiogenics and radiotherapy.
    Shannon AM; Williams KJ
    J Pharm Pharmacol; 2008 Aug; 60(8):1029-36. PubMed ID: 18644195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
    Horsman MR; Siemann DW
    Cancer Res; 2006 Dec; 66(24):11520-39. PubMed ID: 17178843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenesis inhibitors in cancer therapy.
    Dredge K; Dalgleish AG; Marriott JB
    Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulating the tumor microenvironment to improve radiotherapy.
    Maity A
    Retina; 2009 Jun; 29(6 Suppl):S32-3. PubMed ID: 19553796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents.
    Ma BB; Bristow RG; Kim J; Siu LL
    J Clin Oncol; 2003 Jul; 21(14):2760-76. PubMed ID: 12860956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiangiogenic therapies in breast cancer.
    Sarmiento R; D'Andrea MR; Cacciamani F; Salerno F; Gasparini G
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1334-45. PubMed ID: 19943205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.